Ahn KS, Kang KJ. Molecular heterogeneity in intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12(12): 1148-1157 [PMID: 33442444 DOI: 10.4254/wjh.v12.i12.1148]
Corresponding Author of This Article
Keun Soo Ahn, MD, PhD, Associate Professor, Department of Surgery, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, No.1035 Dalgubeol- daero, Dalseo-gu, Daegu 42601, South Korea. ahnksmd@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Dec 27, 2020; 12(12): 1148-1157 Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1148
Molecular heterogeneity in intrahepatic cholangiocarcinoma
Keun Soo Ahn, Koo Jeong Kang
Keun Soo Ahn, Koo Jeong Kang, Department of Surgery, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu 42601, South Korea
Author contributions: Ahn KS designed the study, analyzed the data, and wrote the paper; Kang KJ collected the data and approved the final manuscript.
Supported bythe National Research Foundation of Korea Grant funded by the Korea Government, No. 2018R1C1B3004435.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Keun Soo Ahn, MD, PhD, Associate Professor, Department of Surgery, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, No.1035 Dalgubeol- daero, Dalseo-gu, Daegu 42601, South Korea. ahnksmd@gmail.com
Received: July 20, 2020 Peer-review started: July 20, 2020 First decision: September 24, 2020 Revised: October 1, 2020 Accepted: October 26, 2020 Article in press: October 26, 2020 Published online: December 27, 2020 Processing time: 150 Days and 14.4 Hours
Core Tip
Core Tip: Intrahepatic cholangiocarcinoma (iCCA) is a histopathologically and molecularly heterogeneous tumor. Recent developments in genomic profiling have revealed several molecular markers for poor prognosis and activation of oncogenic pathways. Exploration of molecular characteristics of iCCA in each patient is a major challenge in a clinical setting, and there exists no effective molecular-based targeted therapy. Therefore, the analysis of relevance between molecular and clin-icopathological features is very important. The present analysis showed that the molecular subtypes of iCCA have distinct clinicopathologic features and prognostic differences. For developing effective targeted and personalized therapies based on clinical and molecular understanding, future additional large scale studies are needed.
